Aeterna Zentaris (AEZS) Competitors $3.04 -0.04 (-1.14%) As of 03/28/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsTrendsBuy This Stock AEZS vs. CARA, GRCE, CLDI, ALLK, FNCH, JATT, CVM, CYTH, LIAN, and CMMBShould you be buying Aeterna Zentaris stock or one of its competitors? The main competitors of Aeterna Zentaris include Cara Therapeutics (CARA), Grace Therapeutics (GRCE), Calidi Biotherapeutics (CLDI), Allakos (ALLK), Finch Therapeutics Group (FNCH), JATT Acquisition (JATT), CEL-SCI (CVM), Cyclo Therapeutics (CYTH), LianBio (LIAN), and Chemomab Therapeutics (CMMB). These companies are all part of the "pharmaceutical products" industry. Aeterna Zentaris vs. Cara Therapeutics Grace Therapeutics Calidi Biotherapeutics Allakos Finch Therapeutics Group JATT Acquisition CEL-SCI Cyclo Therapeutics LianBio Chemomab Therapeutics Aeterna Zentaris (NASDAQ:AEZS) and Cara Therapeutics (NASDAQ:CARA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, community ranking, institutional ownership, risk, media sentiment, profitability, valuation, dividends and earnings. Which has more risk & volatility, AEZS or CARA? Aeterna Zentaris has a beta of 1.55, indicating that its stock price is 55% more volatile than the S&P 500. Comparatively, Cara Therapeutics has a beta of 0.5, indicating that its stock price is 50% less volatile than the S&P 500. Do institutionals & insiders have more ownership in AEZS or CARA? 0.7% of Aeterna Zentaris shares are owned by institutional investors. Comparatively, 44.7% of Cara Therapeutics shares are owned by institutional investors. 0.1% of Aeterna Zentaris shares are owned by company insiders. Comparatively, 3.1% of Cara Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has better earnings & valuation, AEZS or CARA? Aeterna Zentaris has higher earnings, but lower revenue than Cara Therapeutics. Cara Therapeutics is trading at a lower price-to-earnings ratio than Aeterna Zentaris, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAeterna Zentaris$2.37M2.30-$16.55M-$14.86-0.20Cara Therapeutics$7.14M3.30-$118.51M-$21.01-0.25 Does the MarketBeat Community favor AEZS or CARA? Cara Therapeutics received 248 more outperform votes than Aeterna Zentaris when rated by MarketBeat users. Likewise, 72.34% of users gave Cara Therapeutics an outperform vote while only 58.85% of users gave Aeterna Zentaris an outperform vote. CompanyUnderperformOutperformAeterna ZentarisOutperform Votes41958.85% Underperform Votes29341.15% Cara TherapeuticsOutperform Votes66772.34% Underperform Votes25527.66% Do analysts rate AEZS or CARA? Cara Therapeutics has a consensus price target of $27.84, suggesting a potential upside of 440.58%. Given Cara Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cara Therapeutics is more favorable than Aeterna Zentaris.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aeterna Zentaris 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Cara Therapeutics 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media favor AEZS or CARA? In the previous week, Aeterna Zentaris and Aeterna Zentaris both had 1 articles in the media. Cara Therapeutics' average media sentiment score of 1.87 beat Aeterna Zentaris' score of 0.00 indicating that Cara Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Aeterna Zentaris Neutral Cara Therapeutics Very Positive Is AEZS or CARA more profitable? Aeterna Zentaris has a net margin of -760.32% compared to Cara Therapeutics' net margin of -1,099.76%. Aeterna Zentaris' return on equity of -83.45% beat Cara Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aeterna Zentaris-760.32% -83.45% -45.76% Cara Therapeutics -1,099.76%-367.97%-107.43% SummaryCara Therapeutics beats Aeterna Zentaris on 9 of the 16 factors compared between the two stocks. Remove Ads Get Aeterna Zentaris News Delivered to You Automatically Sign up to receive the latest news and ratings for AEZS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AEZS vs. The Competition Export to ExcelMetricAeterna ZentarisPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.45M$6.90B$5.63B$7.84BDividend YieldN/A2.75%5.33%4.01%P/E Ratio-0.207.2623.5518.73Price / Sales2.30218.61388.1990.75Price / CashN/A65.6738.1734.64Price / Book0.206.386.894.23Net Income-$16.55M$142.34M$3.20B$247.47M7 Day Performance-5.00%-5.15%-3.06%-2.29%1 Month Performance4.83%-7.55%1.51%-5.81%1 Year Performance-65.30%-11.06%9.35%-0.94% Aeterna Zentaris Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AEZSAeterna ZentarisN/A$3.04-1.1%N/A-65.3%$5.45M$2.37M-0.2020Gap DownCARACara Therapeutics3.9754 of 5 stars$5.12-0.2%$27.84+443.8%-52.8%$23.42M$7.14M-0.2480Analyst ForecastPositive NewsGap DownGRCEGrace Therapeutics2.4272 of 5 stars$2.29+5.0%$12.00+424.0%N/A$23.22MN/A-1.97N/APositive NewsCLDICalidi Biotherapeutics2.204 of 5 stars$0.87+2.2%$16.67+1,817.9%N/A$23.00M$50,000.000.0038News CoverageGap DownALLKAllakos4.6072 of 5 stars$0.25+2.8%$2.00+687.7%-81.7%$22.68MN/A-0.13190Short Interest ↓Positive NewsFNCHFinch Therapeutics GroupN/A$13.75+0.7%N/A+440.6%$22.08M$110,000.00-1.56190JATTJATT AcquisitionN/A$1.28+18.5%N/A-50.8%$22.08MN/A0.003High Trading VolumeCVMCEL-SCIN/A$0.28-6.5%N/A-87.5%$21.94MN/A-0.5943Analyst ForecastHigh Trading VolumeCYTHCyclo Therapeutics2.8614 of 5 stars$0.66-5.6%$0.95+43.7%N/A$21.76M$870,725.00-0.739Upcoming EarningsShort Interest ↓LIANLianBioN/A$0.20flatN/A-41.2%$21.61MN/A-0.25110Gap DownCMMBChemomab Therapeutics3.4706 of 5 stars$1.50+6.4%$9.00+500.0%+45.1%$21.54MN/A-1.5020Short Interest ↓News CoverageGap Down Remove Ads Related Companies and Tools Related Companies CARA Alternatives GRCE Alternatives CLDI Alternatives ALLK Alternatives FNCH Alternatives JATT Alternatives CVM Alternatives CYTH Alternatives LIAN Alternatives CMMB Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AEZS) was last updated on 3/30/2025 by MarketBeat.com Staff From Our PartnersTrump to unlock 15-figure fortune for America (May 3rd) ?We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men...Paradigm Press | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredWall Street’s “AI Oracle” Reveals Next Big Tech PlayA tiny American tech company could be at the center of the next big AI breakthrough. Wall Street's "AI Orac...InvestorPlace | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredTermination: 18F (read immediately)Have you ever heard of the government's 18F program? It helped manage digital services across the governmen...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aeterna Zentaris Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aeterna Zentaris With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AEZS Stock Free AEZS Stock Alerts